Last updated: March 9, 2026
What is NDC 59651-0276?
NDC 59651-0276 is a drug product identified by the National Drug Code (NDC). This code corresponds to Rilzabrutinib (Tirasemtib), a BTK (Bruton's tyrosine kinase) inhibitor developed for immune-mediated diseases, including autoimmune disorders and certain cancers. It is under clinical investigation and not yet approved by the FDA for widespread commercial sale.
Current Market Landscape
Development Status
- Phase: Clinical trials ongoing (as of Q1 2023).
- Indications: Autoimmune diseases, including pemphigus vulgaris; potential for other hematologic malignancies.
- Competitors: Similar drugs include ibrutinib (Imbruvica), acalabrutinib (Calquence), and tirabrutinib (Tirabrutinib).
Patent and Regulatory Timeline
- Patent protection: Expected to be filed following approval, typically lasting 20 years from filing.
- Regulatory pathway: Fast-track or orphan drug designation pending for certain indications, possibly accelerating approval timelines.
Market Size and Potential Demand
| Concept |
Estimate |
| Autoimmune disease prevalence |
4 million patients in the U.S. |
| Pemphigus vulgaris prevalence |
Approx. 50,000 worldwide |
| Estimated Rx initiation rate |
10-15% of eligible patients annually |
| Total addressable market (TAM) |
$30-$50 billion globally |
Source: [1], [2], [3]
Competitive Landscape
| Drug |
Mechanism |
Approval Status |
Annual Sales (2022) |
Key Indications |
| Ibrutinib |
BTK inhibitor |
Approved |
$8.2 billion |
Chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia |
| Acalabrutinib |
Selective BTK inhibitor |
Approved |
$1.2 billion |
CLL, mantle cell lymphoma |
| Tirabrutinib |
BTK inhibitor |
Approved (Japan), trial phase elsewhere |
N/A |
B-cell malignancies, autoimmune diseases |
Price Projection
Current Pricing Context
- Ibrutinib: Approx. $150,000–$170,000 annually per patient.
- Acalabrutinib: Around $160,000 annually.
- Tirabrutinib (marketed in Japan): Estimated at $120,000.
Projected Pricing for NDC 59651-0276
- First-year launch price: $125,000–$140,000 per patient annually.
- Pricing strategies: Based on comparable BTK inhibitors, discounts may occur for payer negotiations; initial list prices tend to climb for new therapies.
- Potential for biosimilar or generic entrants: In 10–15 years post-approval, prices may decline by 50% or more.
Volume and Revenue Forecasts (5-year projection)
| Year |
Prescriptions (est.) |
Revenue (est.) |
Notes |
| 2024 |
1,000 – 2,000 |
$125M–$280M |
Conservative launch with initial uptake |
| 2025 |
5,000 – 8,000 |
$625M–$1.12B |
Adoption accelerates with expanded indications |
| 2026 |
10,000 – 15,000 |
$1.25B–$2.1B |
Uptake driven by approval expansion |
| 2027 |
15,000 – 20,000 |
$1.88B–$2.8B |
Peak market penetration |
| 2028 |
20,000 – 25,000 |
$2.5B–$3.5B |
Stabilization or saturation |
These estimates depend on clinical success, regulatory approval, insurance reimbursement, and competitor actions.
Key Factors Influencing Market and Pricing
- Regulatory approval: Delays could push commercialization to 2025+.
- Unmet medical need: High for rare autoimmune diseases, supporting premium pricing.
- Pricing negotiations: Payer resistance to high launch prices could pressure discounts.
- Market penetration: Physician adoption, formulary inclusion, and patient access programs.
Risks and Opportunities
Risks
- Development delays or failures.
- Competition from established BTK inhibitors.
- Regulatory hurdles, especially in non-U.S. markets.
- Payer resistance to high-cost drugs.
Opportunities
- Expansion into rare, underserved autoimmune indications.
- Breakthrough therapy designation could accelerate market entry.
- Potential for combination therapies with existing immunomodulators.
- Patent extension or new formulation patents could extend revenue life.
Summary
NDC 59651-0276, representing rilzabrutinib, is in clinical development for autoimmune and hematologic indications. Market entry is anticipated within 2–3 years, with initial pricing aligned with existing BTK inhibitors ($125,000–$140,000/year). Market size estimates suggest a potential multi-billion dollar revenue stream, contingent on successful clinical outcomes, regulatory approval, and payer acceptance.
Key Takeaways
- Rilzabrutinib is in late-stage clinical trials targeting autoimmune diseases.
- Launch price projected at $125,000–$140,000 annually.
- Market size could reach $3 billion annually by 2028.
- Competition from existing BTK inhibitors like ibrutinib influences pricing and market share.
- Regulatory delays or failure to demonstrate clear advantages could restrict revenue potential.
FAQs
Q1: When is rilzabrutinib expected to be approved?
Approval timelines depend on ongoing trial results; regulatory submissions could be made in 2024–2025.
Q2: How does rilzabrutinib distinguish itself from existing BTK inhibitors?
Potential benefits include improved safety profiles, efficacy in autoimmune diseases, or oral dosing convenience, pending clinical data.
Q3: What factors could reduce projected revenues?
Market access challenges, payer resistance, competition, and slower-than-anticipated adoption.
Q4: What is the typical patent protection length for new drugs like rilzabrutinib?
Patents generally last 20 years from filing, with data exclusivity grants potentially extending market protection.
Q5: How does the pricing of rilzabrutinib compare globally?
Prices will vary; in markets like Japan, prices may be lower, and reimbursement policies differ.
References
[1] American Autoimmune Related Diseases Association. (2022). Autoimmune disease prevalence data.
[2] QuintilesIMS. (2022). US autoimmune disease market analysis.
[3] EvaluatePharma. (2023). Global immunology drug market and sales data.
